Abstract
The present CoMFA study on thiazolidine-2,4-diones attempts to quantitatively describe the structural features of the compounds for high PPAR-γ agonistic action. A set of 50 compounds was used for the analysis. A training set and a test set were designed consisting of 39 and 11 compounds, respectively. All the molecules were modeled and energy minimized using SYBYL 6.7 software. The molecules were aligned using the most active analog as the template by field fit method. PLS (partial least square) analysis was performed on the training set and statistical parameters like q2, r2, F value and P value were calculated. A final model was generated by excluding four outliers from the training set. Cross Validation was done by leave one out method. The developed CoMFA model showed a good external as well as internal predictivity in most of the compounds with low residual values. The q2 value of the developed model was 0.549 and r2 value was 0.976. Contour plots generated from the steric and electrostatic contributions of this model were used to derive structure-activity relationships and to design a hypothetical molecular structure, which can be used as a lead for design and syntheses of newer molecules.
Keywords: CoMFA, 3D-QSAR, PPAR-γ agonists, Thiazolidine-2,4-diones, Antihyperglycemics
Letters in Drug Design & Discovery
Title: CoMFA Study on Thiazolidine-2,4-diones for their Antihyperglycemic Activity
Volume: 5 Issue: 2
Author(s): M. J. Nanjan, T. K. Praveen, B. Suresh, J. Vergheese, Bijoy J. Desai and B. R. Prashantha Kumar
Affiliation:
Keywords: CoMFA, 3D-QSAR, PPAR-γ agonists, Thiazolidine-2,4-diones, Antihyperglycemics
Abstract: The present CoMFA study on thiazolidine-2,4-diones attempts to quantitatively describe the structural features of the compounds for high PPAR-γ agonistic action. A set of 50 compounds was used for the analysis. A training set and a test set were designed consisting of 39 and 11 compounds, respectively. All the molecules were modeled and energy minimized using SYBYL 6.7 software. The molecules were aligned using the most active analog as the template by field fit method. PLS (partial least square) analysis was performed on the training set and statistical parameters like q2, r2, F value and P value were calculated. A final model was generated by excluding four outliers from the training set. Cross Validation was done by leave one out method. The developed CoMFA model showed a good external as well as internal predictivity in most of the compounds with low residual values. The q2 value of the developed model was 0.549 and r2 value was 0.976. Contour plots generated from the steric and electrostatic contributions of this model were used to derive structure-activity relationships and to design a hypothetical molecular structure, which can be used as a lead for design and syntheses of newer molecules.
Export Options
About this article
Cite this article as:
Nanjan J. M., Praveen K. T., Suresh B., Vergheese J., Desai J. Bijoy and Prashantha Kumar R. B., CoMFA Study on Thiazolidine-2,4-diones for their Antihyperglycemic Activity, Letters in Drug Design & Discovery 2008; 5 (2) . https://dx.doi.org/10.2174/157018008783928409
DOI https://dx.doi.org/10.2174/157018008783928409 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Plasma Nesfatin-1 and Obestatin Levels in Patients with Type 2 Diabetes Mellitus
Current Pharmaceutical Design Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews Food Fortification with Omega-3 Fatty Acids; Microencapsulation as an Addition Method
Current Nutrition & Food Science Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Pleiotropic Effects of ARB on Dyslipidemia
Current Vascular Pharmacology Glaucoma Disease: A Survey
Current Medical Imaging Overview of Current and Upcoming Strategies Implied for the Therapy of Type 2 Diabetes Mellitus
Current Diabetes Reviews Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bioinformatics Analysis of Functional Protein Sequences Reveals a Role for Tumor Necrosis Factor-α and Nitric Oxide in Insulin Resistance Syndrome
Current Nutrition & Food Science Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Diabetes Care: Risk Factors, Prediction, Prevention, and Individualized Treatment
Infectious Disorders - Drug Targets A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”
Current Pharmaceutical Design Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Potential Applications of <i>Sarcopoterium Spinosum</i> as Medicinal Plants: Overview and Future Trends
Current Traditional Medicine